Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)

NCT06659445 is registered in ClinicalTrials.gov with ONL Therapeutics as lead sponsor.

NCT NCT06659445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06659445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)
Lead sponsor
ONL Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
October 28, 2025
Completion date
November 30, 2028
Enrollment
324 (estimated)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

age - related macular degeneration (amd), geographic atrophy (ga)